PortalPublikationenCarboplatin and pegylated liposomal doxorubicin versus carbo...

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients

Standard

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients : results from a subset analysis of the CALYPSO phase III trial. / Gladieff, L; Ferrero, A; De Rauglaudre, G; Brown, C; Vasey, P; Reinthaller, A; Pujade-Lauraine, E; Reed, N; Lorusso, D; Siena, S; Helland, H; Elit, L; Mahner, S.

in: ANN ONCOL, Jahrgang 23, Nr. 5, 01.05.2012, S. 1185-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gladieff, L, Ferrero, A, De Rauglaudre, G, Brown, C, Vasey, P, Reinthaller, A, Pujade-Lauraine, E, Reed, N, Lorusso, D, Siena, S, Helland, H, Elit, L & Mahner, S 2012, 'Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial', ANN ONCOL, Jg. 23, Nr. 5, S. 1185-9. https://doi.org/10.1093/annonc/mdr441

APA

Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., Helland, H., Elit, L., & Mahner, S. (2012). Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. ANN ONCOL, 23(5), 1185-9. https://doi.org/10.1093/annonc/mdr441

Vancouver

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. ANN ONCOL. 2012 Mai 1;23(5):1185-9. https://doi.org/10.1093/annonc/mdr441

Bibtex

@article{4e2a5f90b1cc482582a981e6fb19b9bb,
title = "Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial",
abstract = "BACKGROUND: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial.PATIENTS AND METHODS: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤ 12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety.RESULTS: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = 183, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58-0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm).CONCLUSION: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.",
keywords = "Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Disease-Free Survival, Doxorubicin, Drug Resistance, Neoplasm, Female, Humans, Middle Aged, Ovarian Neoplasms, Paclitaxel, Platinum Compounds, Polyethylene Glycols, Recurrence, Treatment Outcome, Young Adult",
author = "L Gladieff and A Ferrero and {De Rauglaudre}, G and C Brown and P Vasey and A Reinthaller and E Pujade-Lauraine and N Reed and D Lorusso and S Siena and H Helland and L Elit and S Mahner",
year = "2012",
month = may,
day = "1",
doi = "10.1093/annonc/mdr441",
language = "English",
volume = "23",
pages = "1185--9",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients

T2 - results from a subset analysis of the CALYPSO phase III trial

AU - Gladieff, L

AU - Ferrero, A

AU - De Rauglaudre, G

AU - Brown, C

AU - Vasey, P

AU - Reinthaller, A

AU - Pujade-Lauraine, E

AU - Reed, N

AU - Lorusso, D

AU - Siena, S

AU - Helland, H

AU - Elit, L

AU - Mahner, S

PY - 2012/5/1

Y1 - 2012/5/1

N2 - BACKGROUND: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial.PATIENTS AND METHODS: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤ 12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety.RESULTS: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = 183, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58-0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm).CONCLUSION: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.

AB - BACKGROUND: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial.PATIENTS AND METHODS: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤ 12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety.RESULTS: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = 183, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58-0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm).CONCLUSION: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.

KW - Adenocarcinoma

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Disease-Free Survival

KW - Doxorubicin

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Platinum Compounds

KW - Polyethylene Glycols

KW - Recurrence

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1093/annonc/mdr441

DO - 10.1093/annonc/mdr441

M3 - SCORING: Journal article

C2 - 21976386

VL - 23

SP - 1185

EP - 1189

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 5

ER -